Platelet glycoprotein IIb/IIIa receptor blockade therapy for large coronary aneurysms and thrombi in Kawasaki disease

Cathet Cardiovasc Diagn. 1998 Nov;45(3):264-8. doi: 10.1002/(sici)1097-0304(199811)45:3<264::aid-ccd10>3.0.co;2-2.

Abstract

A 4-month-old girl with Kawasaki disease, large coronary artery aneurysms, and coronary thrombi was treated with standard therapy followed by abciximab, a platelet glycoprotein IIb/IIIa antagonist, in addition to standard heparin and warfarin sodium anticoagulation and low-dose aspirin. She did not develop evidence of ischemia, had no complications from the therapy, and showed resolution of the aneurysms and thrombi after 6 wk of therapy.

Publication types

  • Case Reports

MeSH terms

  • Abciximab
  • Antibodies, Monoclonal / therapeutic use
  • Anticoagulants / therapeutic use
  • Aspirin / therapeutic use
  • Cardiac Catheterization
  • Coronary Aneurysm / complications
  • Coronary Aneurysm / diagnosis
  • Coronary Aneurysm / drug therapy*
  • Coronary Angiography
  • Coronary Thrombosis / complications
  • Coronary Thrombosis / diagnosis
  • Coronary Thrombosis / drug therapy*
  • Drug Therapy, Combination
  • Echocardiography
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoglobulin Fab Fragments / therapeutic use
  • Immunoglobulins, Intravenous / therapeutic use
  • Infant
  • Mucocutaneous Lymph Node Syndrome / blood
  • Mucocutaneous Lymph Node Syndrome / complications*
  • Mucocutaneous Lymph Node Syndrome / diagnosis
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Platelet Count
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Anticoagulants
  • Immunoglobulin Fab Fragments
  • Immunoglobulins, Intravenous
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Aspirin
  • Abciximab